GlassScriptPhysician profile
Tamecka Knight
NPI 1982806709
$4,349.97
in general payments reported to CMS, 2019-2025
30 companies · $826 in 2025
The $826 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $745 · 2022: $790 · 2023: $1,060 · 2024: $929 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $916.96 | 2021-2025 | Bexsero, Arexvy, Pediarix |
| Genzyme Corporation | $468.45 | 2023-2024 | |
| Abbvie INC. | $460.98 | 2021-2025 | |
| Pfizer INC. | $330.39 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $311.26 | 2021-2022 | |
| Inspire Medical Systems, INC. | $272.04 | 2024-2025 | Inspire |
| Cranial Technologies, INC | $167.18 | 2022-2025 | Doc Band |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Kyowa Kirin, INC. | $121.86 | 2025 | |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $111.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.13 | 2023 | Jardiance |
| Dexcom, INC. | $78.03 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amgen INC. | $77.60 | 2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Vapotherm INC | $66.17 | 2023 | Vapotherm |
| Biogen, INC. | $61.43 | 2024 | |
| Coloplast Corp | $56.33 | 2023 | Titan |
| Phadia US INC. | $48.36 | 2021-2024 | Immunocap |
| Sanofi Pasteur INC. | $46.76 | 2024 | |
| Lnhc, INC | $45.30 | 2025 | Zelsuvmi |
| Seqirus USA INC | $44.66 | 2024-2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $42.86 | 2022-2024 | Vaxneuvance, Gardasil, Vaqta |
| Kowa Pharmaceuticals America, INC. | $36.84 | 2025 | Zoryve |
| Organon LLC | $29.63 | 2025 | Vtama |
| Sobi, INC | $29.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.01 | 2022 | |
| Alk-Abello, INC | $16.02 | 2024 | Grastek, Odactra |
| Cumberland Pharmaceuticals, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamecka Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.